HSP90AA1 and familial pancreatic carcinoma: Subsequently, they found that the natural product bound to HSP90 CTD, leading to disruption of HSP90-CDC37 interactions.507,508 The treatment of celastrol A resulted in the downregulation of kinase client AKT and CDK, and further exhibited anti-proliferative activity against pancreatic cancer cells (IC50 = 3.0 μM).